

HIGH-
LIGHTS

HIGH-

LIGHTS

HIGH-

LIGHTS



HIGH-

LIGHTS

HIGH-

LIGHTS

hollandbio



**BI ♥
TECH
FOR
LIFE**

hollandbio

#foreword

WISER THAN OUR (TEN!) YEARS

Hollandbio is ten years old! We've grown like a weed, amassing a considerable membership (>260 companies) and an ever-stronger team (15 colleagues), and that translates into the one thing that matters most: our collective impact growing stronger (something which cannot be expressed in a single number).

This is only possible thanks to our amazing members. Their tremendous trust allows us to focus on what's best for the pioneers in our industry. Because what's good for these frontrunners today is good for all of them tomorrow, next week or next year. And not only good for just our companies, but also good for society. Our members' missions are to improve health, protect the climate, and feed the world. Biotech's role here is incredible, and will only get bigger. Hollandbio is doing everything we can to improve the long and risky road from lab to practice. We get rid of the obstacles and make sure incentivizing policies are in place.

Too often we see momentum accelerate from such policies, but the lack of an integrated approach slams on the brakes. We're in a hurry, and there's no time to lose. So on top of our well-known dedicated and passionate approach, we will become even more outspoken to achieve the much-needed breakthroughs.



Of course, in addition to our advocacy, we are also fully committed to strengthening the network with leading events, and to helping companies make business easier thanks to our member benefits.

Over the past decade, we have built hollandbio together with members and stakeholders. We are valued and trusted, and we will maximize our impact in the years to come. Every day, the board and the team are honored to represent a sector that is so important to our future – you are a source of inspiration for us. We are counting on your continued support!



Annemiek Verkamman
Managing Director



Oscar Goddijn
Chair

#contents

AT A GLANCE

Biotech makes life better

Hollandbio is the advocacy group for biotech companies in the Netherlands. Together we work towards our future vision: a society where biotech contributes its all to health, sustainability and economic growth.

8

The revolutionary growth of biotech

Name a challenge of our time and you will find biotech part of the solution. That's why the global biotech sector is growing in leaps and bounds.

10

Dutch biotech in the lead

These innovative examples from the sector speak for themselves, and give Dutch biotech a name. We should embrace that.

14

Hollandbio unites the sector

The stronger hollandbio is, the more united biotech becomes. Our members are paramount.

18

Meet hollandbio

Wondering who's behind hollandbio? Meet our board and office.

20

Hollandbio's three programs

Together with our members, we run three structured and methodical programs to maximize the success of the biotech sector.

22

Rock-solid innovation climate

We work to create fertile ground where biotech companies can grow and thrive.

26

Technology for a sustainable future

With biotech innovation in high gear, the future is healthy, sustainable and animal-friendly.

34

Personalized health

Every human being is different. But when we're sick, we all want the same thing: to get better. In fact, we would rather just stay healthy. Hollandbio advocates for radical advances in healthcare.

42

The face of Dutch biotech

We can't remove the hurdles on our own. Hollandbio operates in a vibrant ecosystem and dynamic field.

52

Hollandbio's events connect the sector

From large and compelling to small and specialized: our events strengthen the biotech network.

60

Hollandbio's member benefits

With our member benefits, hollandbio makes doing business in biotech a bit easier for our members.

70

Join hollandbio

We already count thousands of life sciences professionals and over 260 biotech companies in our constituency. We hope you'll join us, too!

72



#strategy

BIOTECH MAKES LIFE BETTER

Despite being a small country, the Netherlands is known for some pretty big accomplishments. For years we've been inventing new solutions that make our lives better. Our country was a frontrunner during the industrial revolution, the agricultural revolution, and now biotech. And yes: here, too, we are once again leading the way.

Biotech has brought us many wonderful things. It gives us the ability to cure patients with incurable diseases, make materials like plastic without using fossil resources, relegate animal testing and intensive animal husbandry to the past, and grow fruits and vegetables on unusable land.

If we want a beautiful world to pass on to the next generation, biotech is part of the solution. Only if we pursue this development together will we create the right conditions for biotech. So let's embrace biotech and agree on the rules of the game. Let's join hands to make sure we don't hinder the development of a more beautiful world for future generations.

Hollandbio wants to amplify the contribution that biotech can make. That's why we aim for maximum impact. We increase public support for biotech innovations by putting them even more firmly on the map. We strengthen our leading position as an authority and champion of biotech, and we are the industry's trusted partner. Our extensive programs work to create an ecosystem and the right rulebooks to let biotech innovations flourish. This can be a challenge, because new biotech applications continually challenge the status quo of the existing system. This requires adaptability, and sometimes even systemic change. But we're not satisfied until the results of our work are meaningful, visible and tangible for biotech leaders.

Biotech makes life better. That's the firm conviction we share with increasing numbers of people. We are reassured by the growing understanding that biotech is part of the solution - because only together can we make it happen.

We are hollandbio. The advocacy group of the biotech sector.



See for yourself
how we put
biotech in
the spotlight.
Watch the
film:



Management Team hollandbio: Wieteke, Annemiek & Timen.

#biorevolution

THE REVOLUTIONARY GROWTH OF BIOTECH

We're right in the middle of the biotech revolution

Reducing CO₂ emissions, fighting a pandemic, giving patients a new lease on life, enough food for all. Name a challenge of our time and biotech contributes to the solution. It's not for nothing that governments, research institutes and companies worldwide invest a great deal in the scientific and commercial development of this sector - a sector that's growing in leaps and bounds.

It's hard to see a revolution when you're in it. But the fact is that developments in biotech are happening strikingly fast. More and more, we know what happens in and between all kinds of (micro) organisms. Major breakthroughs in biology, such as the discovery of CRISPR-Cas, coincide with other developments such as rapidly advancing automation and the rise of artificial intelligence. This is creating a momentum that is changing our lives so much that the McKinsey Global Institute speaks of the "biorevolution". We can manipulate organisms on a scale and in ways that were unthinkable before, opening up a wealth of new possibilities, especially in healthcare, food production and chemistry.

The Netherlands as a potential frontrunner

The Netherlands has everything it needs to become the European biotech hub. We put a lot of money into research, and we are innovative and agile. Dutch research institutes are often global leaders in biotech. We have major players in chemistry, health and plant breeding, and a thriving biotech landscape with hundreds of start-ups and scale-ups. Together with other strengths, such as a well-trained workforce and excellent infrastructure, the Netherlands has every chance of reaping the benefits of the biorevolution.

According to McKinsey, cashing in on the opportunities of the biorevolution will yield 27 to 37 billion euros per year for the Netherlands by 2040. This figure encompasses the economic value of social improvements such as better health, life years gained, lower greenhouse gases, higher yields in agriculture, and more efficient and sustainable materials and industrial processes. And this calculation does not incorporate value from other effects from the biorevolution, such as improved well-being, indirect productivity gains, and economic outcomes around employment and GDP. Not only could the biorevolution have a major impact on society, but also on our country's innovation capacity, competitiveness and overall prosperity.

IMPACT FROM

27 TO 37
BILLION
EURO PER YEAR
IN 2040

Researchers and entrepreneurs are ready

Biotech researchers and determined entrepreneurs are eager to develop increasingly sophisticated and innovative applications. But is society ready for these revolutionary changes? Every innovation, every change comes with resistance. McKinsey estimates that 70% of the social and economic benefits of the biorevolution hinge on how firmly we as a society embrace its innovations.

For the biorevolution to reach its full potential, we must invest not only in technological advances, but also in building trust and understanding around biotech, both among politicians and policymakers as well as the general public. After all, it's in everyone's interest that we all benefit equally from the innovations and success of this revolution.


70%

OF THE SOCIAL AND ECONOMIC
BENEFITS STAND OR FALL THROUGH
THE EMBRACING SOCIETY



Want to know more?
Click or scan the QR code.

The best route to a better world



hollandbio

#momentum

DUTCH BIOTECH IN THE LEAD

Despite being a small country, the Netherlands is known for some pretty big accomplishments. And once again, we're leading the way in biotech. This is also why this key technology takes a prominent role in various policy analyses, strategies and plans for our national future. Biotech plays an important part in both the National Technology Strategy and the Growth Markets Analysis, and the Dutch government is working on a government-wide, integrated vision for biotech. Hollandbio is committed to ensuring that these valuable plans don't remain just words, but that we turn them into actions that further advance Dutch biotech.

Although the Netherlands is a frontrunner in biotech, the European context is also hugely important: most of the regulations you encounter as a biotech pioneer originate in Brussels. The European Commission and other member states also recognize the importance of the sector. The upcoming EU Biotech Act is therefore a great opportunity to give the sector a firm push in the right direction.

From illness to health

The convergence of biology, artificial intelligence and other key technologies in the biorevolution is reflected in the health field in

Biotech trend analysis



Trendanalyse biotechnologie 2023. Tijd voor een integrale visie

De ontwikkelingen in de biotechnologie gaan razendsnel. De beloften zijn groot: biotechnologie kan een belangrijke bijdrage leveren aan

Duidelijke focus op biotechnologie in Nationale Toekomststrategie


LIJZERSTERK INNOVATIEKLIMAAT, HOLLANDBIO, INNOVATIEKLIMAAT, UITSELICHT

23 JANUARI 2024

Nederland kiest voor biotech! We zijn bij hollandbio erg blij met de keuzes die EZK maakt in de afgelopen vrijdag gepubliceerde **Nationale Toekomststrategie**. Het geeft hierin voorrang aan die technologieën waar Nederland wetenschappelijk in uitblinkt en die gaan zorgen voor economische groei en ons toekomstig verdienvermogen van Nederland. En dat niet alleen, door hier prioriteit aan te geven en in te investeren maken we werk van het oplossen van maatschappelijke uitdagingen. Met innovaties die vanuit Nederland gezondheid en duurzaamheid nog beter maken. Win-win dus!

Biotech in NTS

Pioneering science in business



Hans Clevers gaat nieuwe uitdaging aan bij Roche

Met ingang van 18 maart 2022 wordt Hans Clevers, groepsleider bij het Hubrecht Instituut, benoemd tot hoofd van Roche Pharma Research and Early Development (pREED) en lid van het Corporate Executive Committee bij Roche in Basel, Zwitserland. In deze nieuwe rol zal hij onderzoek naar de ontwikkeling van medicijnen voor een breed scala aan ziekten leiden. Hans blijft als adviseur/gastonderzoeker nauw betrokken bij zijn onderzoeksgroep aan het Hubrecht Instituut.



Commission takes action to boost biotechnology and biomanufacturing in the EU

PR **COMMUNICATIONS** Today, the Commission has presented a series of targeted actions to boost biotechnology and biomanufacturing in the EU. The Commission, in Building the Future with Nature, identifies the challenges and barriers and proposes to tackle them. In line with the Commission on the long-term competitiveness of the EU.

PR **COMMISSION** The advances in the sciences, supported by digitalisation and artificial intelligence (AI), and the potential of solutions based on biology to solve societal issues, make biotechnology and biomanufacturing one of the most promising technological areas of this century. They can help the EU to accelerate its agricultural, forestry, energy, food and third sectors and industry. In addition, these technologies can contribute to a more competitive and resilient EU, that provides better healthcare for its citizens, and supports its citizens and industry.

EC EU Biotech Act

various ways in the Netherlands. A good example is the collaboration between Hartwig Foundation and Genomescan with the healthcare field on using (molecular) diagnostics and its data to improve patient care. Or take Roche, which engaged top scientist Hans Clevers to set up the Institute for Human Biology, where they are accelerating and improving the route from lab to clinic by applying organoids and organs-on-a-chip.

With biotech, we can treat patients earlier and better in the disease process, contributing to the shift from illness to health. One notable example is the treatment of young children with metachromatic leukodystrophy (MLD), a rare genetic disorder. Not only is there now a gene therapy available for it, but we are now including this disorder in the neonatal heel prick in the Netherlands, meaning we can actually start treatment early on. What's more, new drugs are coming onto the market for conditions that affect large groups of Dutch citizens, like diabetes or obesity, which also lead to considerable suffering and healthcare costs.

Well-known products, but better

Biotech allows us to make food and materials that we have consumed and used for decades, but with less animal suffering and fossil resources. Whether better crops, cultured meat, innovative fermentation or biobased feedstocks, such innovations can, in their own way, be a crucial part of solving the challenges we face in food, agriculture and the climate. The Netherlands has always been a frontrunner in innovative agriculture, and is proving itself once again when it comes to biotech: our country was the EU's first to sample cultured meat at [Meatable](#) and [Mosa Meat](#), and now preparations are underway to make this possible for products from innovative fermentation, as well.



See more?

Click or scan
the QR code.



Hollandbio's Annemiek
tastes the Mosa Burger.

In addition to food, biotech also has numerous applications in materials that make value chains and end-products cleaner and greener. From companies such as Outlander Materials and Photanol, which are developing new materials and building blocks for bioplastics, to dsm-firmenich and NoPalm Ingredients, which market ingredients for perfumes and cosmetics, among others.

Public and private investments in biotech

With its excellent knowledge, the Netherlands has long been at the forefront of biotech. But there is still room to improve how we convert this knowledge into businesses and innovations that lead to social and economic impact, in our country and beyond. In an effort to break through this hurdle, hollandbio, J&J, dsm-firmenich, Dutch universities, university medical centers and colleges came together and initiated the National Growth Fund program Biotech Booster. The first 54 projects have received funding to get new innovations investment-ready faster, better and with the help of the expertise and guidance of experienced biotech entrepreneurs.

Although the (inter)national financing climate for starting and growing biotech companies remains extremely difficult, several big hits have been achieved in recent years: from IPOs, share issues, licensing agreements and series A, B, and C financing rounds, to partnerships, Innovation Credits and European grants. Every year, Dutch biotech companies manage to secure countless millions of euros for the fastest and best possible path from lab to society. Take Cradle, for example. Cradle uses AI to help develop better proteins, and it raised 73 million euros to do so. Or VectorY Therapeutics, which is developing an innovative gene therapy platform to treat muscle and nerve diseases - it completed a funding round of 129 million euros.



#sector info


HOLLANDBIO UNITES THE SECTOR

With conviction and pride, hollandbio dedicates itself to Dutch biotech leaders every day. As a privately funded association of and for biotech companies, hollandbio is nowhere without our members. In short, our more than 260 members come first.


Our constituency is a good reflection of the sector: from start-ups and SMEs to multinationals focused on health, nutrition and materials. And like the sector, hollandbio is growing year after year. The more members, the stronger we are, and the more we can achieve for the sector. We continually invest in strengthening our advocacy, creating valuable networking opportunities and offering relevant benefits, thus engaging both existing and new members. A strong hollandbio means a solid, united sector - a flywheel for shared growth.

HOLLANDBIO HAS OVER **260** MEMBERS

R&D FOCUS




COMPANY SIZE



THE DUTCH BIOTECH SECTOR COUNTS **1848** COMPANIES

R&D FOCUS



Total number of R&D companies: **734**



Clinical products in development: **276**

Source: Biotechgate 2023

Want to know more?

Click or scan the QR code and read more about the sector.



#about us

MEET HOLLANDBIO

The board of hollandbio

The hollandbio board consists of diehard biotech professionals. Together they form a microcosm of hollandbio's constituency. They represent start-ups, SMEs and multinationals, members active in health and prevention, nutrition and materials, and industrial biotech, and similar members that advance the sector.



Oscar Goddijn
Chair



Willemijn Vader
Vice Chair



Roel Schaapveld
Treasurer



Jan van Veen
Board Member



Linda Dijkshoorn
Board Member



Manuella Wilts
Board Member



Ellen Broug
Board Member



Marcel Jacobs
Board Member

Meet the team behind hollandbio

Our office is the driving force behind hollandbio's activities and is an official [Great Place to Work!](#) Every day we work to remove the hurdles that stand in the way of the sector's success so that biotech innovations contribute their all to a sustainable and healthy society. We manage membership records, organize events, provide discounts and other benefits



to members, collect and analyze information about the industry, address the press on behalf of the industry and so much more. Feel free to browse! If you're looking for specific information on biotech, would like to exchange thoughts, or just feel like having a chat: please [get in touch](#).



Annemiek Verkamman
Managing Director



Wieteke Wouters
Program Director



Timen van Haaster
Public Affairs &
Communications
Director



Britt van de Ven
Program Manager



Casper Brack
Public Affairs &
Communications
Manager



Dora Menting
Program Manager



Dina Diek
Project Manager



Idalia Długosz
Project Manager



Ingrid Vosters
Operations Coordinator



Jacqueline Alling
Management Assistant



Leonie White-Scholten
Project Manager



Max van den Berg
Project Manager




Rianne Hageman
Program Manager



Robbert Wever
Project Manager



Thomas Broekhoff
Project Manager



#programs


HOLLANDBIO'S THREE PROGRAMS

Hollandbio works in programs to maximize our impact. Our programs make it perfectly clear what we stand for and where we're going (the "why"). With this in mind, we work to realize our goals. We pinpoint the bottlenecks and opportunities and devote ourselves to implementing solutions (the "what"). We do this together with our members and partners, in the characteristic hollandbio way (the "how").

Why!


Rock-solid innovation climate

No biotech innovation could exist without the right conditions for entrepreneurship. With plenty of funding in each phase of development, seamless tech transfer, and a business climate that attracts companies and leading talent, the Netherlands is becoming the undisputed Boston of Europe.




Technology for a sustainable future

The IPCC's "Code Red for Humanity" is clear: it is the hour of reckoning. Biotech can help turn the tide by making chemicals, agriculture, animal husbandry and fisheries more sustainable. Today's choices will make or break the future. With biotech innovation in the highest gear, the future will be healthy, sustainable and animal friendly.




Personalized health

Every person is different. But when we get sick, we all want the same thing: to get well. Even better, we just want to stay healthy. Hollandbio advocates for a radically new approach in healthcare: a transition from one-size-fits-all to personalized care, made possible by the innovative power of biotech. This requires substantial investment in improvements: in an accessible health data infrastructure and in the rapid development, implementation and deployment of innovations such as vaccines, AI, prognostics and diagnostics, and the latest treatment options.



What!



How!

Here's how we do it

- Forward-thinking
- Unifying
- Ambitious
- Enterprising
- Transparent



Want to learn more, think along with us, or get involved?

Click or scan the QR code or get in touch with hollandbio's Wieteke.





**I believe
I can try.**

hollandbio

ROCK-SOLID INNOVATION CLIMATE



Despite being a small country, the Netherlands is known for some pretty big accomplishments. For years we have been inventing new solutions that make our lives better – so a good dose of entrepreneurship is essential. This certainly holds for biotech. Imagining and developing biotech products requires not only a lot of knowledge, money and time, but also courage and perseverance: every success stands on the shoulders of many experiments that failed.

Hollandbio wants our dedicated biotech entrepreneurs to have plenty of room to do business. That's why we're committed to a rock-solid innovation climate. We work to ensure sufficient and suitable funding at every stage of development so that promising biotech companies can continue to grow without having to waste time searching for capital. We work to optimize the processes and conditions around knowledge transfer so our national academic excellence has room to drive biotech business and product development. Finally, we are committed to an attractive entrepreneurial climate with favorable and reliable conditions that make it nice to do business in the Netherlands. With the right soil for biotech entrepreneurship, homegrown companies can take root, grow and flourish in our country, and the Netherlands can also become a magnet for international biotech companies and talent.

A look at our results

The choice for biotech

The Netherlands chooses biotech! Our beloved sector enjoys a prominent role in various policy analyses and strategies for the future of the Netherlands. Biomolecular and cell technologies (read: biotech) are among the key technologies of the National Technology Strategy, biotech tops the list of Growth Markets for the Netherlands, and the Trend Analysis on Biotechnology outlines not only how the many biotech applications can contribute to social and economic challenges, but also what needs to be done to capitalize on these opportunities. Europe also sees a future for biotech, and has announced the introduction of the EU Biotech Act to boost our sector. All in all, an excellent starting point for making change: turning buzz words into action, putting the wind in the sails of biotech businesses. Of course, hollandbio is fully involved. #EUBiotechActNow

Biotech companies welcome Health~Holland's SME Call


The SME Call from Health~Holland (Life Sciences & Health "top sector") has been a huge success. SMEs can receive up to 150 thousand euros to fund an R&D employee's work on an industrial private-public project for a period of two years. With our help, the SME Call was developed in 2023 to support SMEs in their collaborations with Dutch research institutes. That the grant meets a need is evident from the numbers: the two rounds in 2023 and 2024 went well over budget. Health~Holland has risen to the occasion and released a total of eight million euros for the continuation of the SME Call in 2025.

Biotech Booster out of the starting blocks

It's been a thorn in hollandbio's side for years: excellent homegrown knowledge struggling to find its way into product development, business and application. Biotech Booster, the unique joint National Growth Fund project of hollandbio, the Universities of the Netherlands, the Dutch Federation of University Medical Centers, the Association of Universities of Applied Sciences, dsm-firmenich and Johnson & Johnson Innovative Medicine, should change this. In 2022, the project received a 250 million euro grant to radically revamp the valorization process in the Netherlands. In 2024, Biotech Booster funded the first 54 projects. Though Biotech Booster is now on its own feet, hollandbio is still closely involved on the foundation's board and Supervisory Board. On to even more impact!

Mapping the funding landscape

Financing is an absolute necessity for biotech companies: no research and development can exist without venture capital. Sometimes the investment opportunities seem limitless, but just as often the market is locked down, and funds, governments and banks prefer to keep a tight hold on the purse strings. Hollandbio closely monitors financial developments, analyzes existing and new funds and grants, and publishes clear "finfographics". Our aim is to share our knowledge and to seize every opportunity to get capital moving in the biotech sector.



Click or scan the QR code to view the infographic.



Biotech on The Hague's radar

Only together can we make room for biotech entrepreneurship. That's why hollandbio maintains contact with the many organizations and people who can contribute to our goals, such as politicians, government, research institutes and financiers. In early 2024, for example, a delegation from the Ministry of Economic Affairs (EZ) and the Netherlands Enterprise Agency (RVO) visited biotech star Genmab, where they spoke about the innovation and entrepreneurial climate in the Netherlands in the presence of several leading entrepreneurs. The main message to EZ and RVO: step on the gas, don't hit the brakes! Later that year, we welcomed Minister for Foreign Trade Reinette Klever to the Bio-Europe in Stockholm, where she met many Dutch biotech companies that were in attendance. The minister was very impressed by the inspired entrepreneurship and innovative perspectives.



Hollandbio's Annemiek with the Ministers of Health, Welfare and Sport and Economic Affairs and Climate at the BIO International Convention.

The work ahead

Hollandbio is committed to a rock-solid innovation climate where biotech companies can put down their roots, grow and thrive. That's why we're working on:

Act now for EUr biotech


Now that The Hague and Brussels have been won over to biotech, it's time to move forward and turn our speeches into resounding action that enables Dutch and European biotech companies to compete on the world stage. This requires quite some effort, because the Dutch and European governments are often hitting the gas and brakes at the same time, causing a standstill. They want to put their weight behind frontrunners, but also stick to a consensus model. They want to drive transition, but are not willing to change the system. They want to boost innovation, but don't want to take any risks.

Hollandbio calls on governments to break this major impasse and get to work on biotech, such as in national plans like the biotech vision and the National Technology Strategy, as well as at the European level in the EU Biotech Act.

ACT NOW FOR EUR FREEDOM



Time to act - EU Biotech Act 2025



Funding, funding, funding

Ask any biotech entrepreneur what their biggest challenge is, and chances are their answer will be funding. Hollandbio won't rest until there is sufficient, suitable financing at every stage of biotech development, whether it means improving or expanding existing arrangements, or tapping into entirely new sources.

Robust business environment

Hollandbio is committed to maintaining and further strengthening our country's business climate. In close contact with our entrepreneurs, we keep a close eye on all issues crucial to a good business climate - such as developments in the tax system, intellectual property, talent, lab and office space, and grid congestion - focusing our sights on those topics where, working together, we can have the most impact.

Want to learn more, think along with us, or get involved?

Click on or scan the QR code or contact hollandbio's [Dora](#), [Robbert](#) or [Max](#).



BIOTECH BOOSTER GETS BIOTECH TO WORK

The Netherlands ranks high in knowledge around biotech, but struggles with valorization. Getting that knowledge into business and product development has proven difficult. This complex problem can only be addressed by close cooperation within the ecosystem.

To form a new national valorization approach for biotech, we developed the idea of the Biotech Booster. Once we created momentum around the problem, we found plenty of support among research institutes and academic hospitals, and a shared ambition to fix it. Together, we submitted an application to the National Growth Fund.

“What matters is not how, but *that* innovation finds its way.”

Annemiek Verkamman, hollandbio



Want to know more about Biotech Booster?
Click or scan the QR code.

2021

1

Problem identified & brought to attention

In-house and external research brings the problem into sharper focus.

2

Initiation of a unique coalition

Universities, UMCs and biotech companies come together!

3

Submission of proposal

The Ministry of OWC submits a proposal to the Growth Fund committee.

4

Plan accepted!

On April 14, 2022, the cabinet allocates 250 million euros for its realization.

5

Biotech Booster established



2024

On to impact with the first projects!

Within the Biotech Booster program, promising ideas receive the financial resources and professional guidance to grow into strong and investable propositions.

€ 17.6 MILLION

GRANTED TO 54 BIOTECH FRONTRUNNERS

TECHNOLOGY FOR A SUSTAINABLE FUTURE



Technology has brought the world unprecedented prosperity. But that prosperity has also come with the depletion and pollution of our planet. It's code red for humanity. Climate change is causing floods, drought and temperature extremes. We have increasing numbers of people to feed, and our consumption is on the rise, on all fronts. In short: the world is desperate for solutions, and preferably soon.

As a country, the Netherlands has been a leader in advancement. We were there in the days of the industrial revolution, the digital revolution, and now we're leading in biotech, too. Biotech brings out the best in our nature to improve humans, animals and the planet. With biotech, we can make high-quality materials like plastics without fossil resources and produce sufficient and healthier food in a way that's more friendly to animals and the environment. If we want to hand a decent world over to the next generation, biotech is a crucial part of the solution.

With the technology for a brighter future program, we're paving the way for smart biotech solutions that make progress without the downsides. We're removing barriers that prevent frontrunners from bringing their plant, food and material innovations to the world. We're building a strong network, advocating for supportive legislation and regulations and clear, common rules, and promoting demand for and the application of biotech products. Our leading biotech sector is a powerful asset for the future of the Netherlands. And if it's up to hollandbio, that future starts now.

A look at our results

Have a taste!

Thanks in part to hollandbio's efforts, the Dutch government was the first in the European Union to allow tastings of cultured meat. Together, the ministries of LNVN and VWS, Mosa Meat and Meatable, the two Dutch cultured meat producers, and hollandbio have drawn up a Code of Practice that makes responsible tasting possible. Fantastic news that was met with great enthusiasm in the national and international media. And the icing on the cake: our own Annemiek was one of the first tasters to sink her teeth into the Mosa Burger. It's been a mouth-watering success: we're now working together with those same ministries and our innovative cultured meat companies on tastings for fermented novel foods.

CRISPR from Europe's own greenhouse

Much to the frustration of science and industry, we still cannot grow or buy CRISPR products in Europe. Modernizing Europe's badly outdated genetic modification legislation should be the answer. The European Commission published a proposal to regulate the application of a number of targeted techniques more proportionally, such as CRISPR-Cas to breed plants. Although hollandbio would much rather see a complete paradigm shift that ends discrimination against products based on the technology used to make it, we think the proposal is a careful step in the right direction. Hollandbio is closely following the developments and is more often than not the first to share solid analysis and positions with our members, policymakers, Permanent Representatives, politicians, journalists and European umbrella bodies. For maximum impact and support, we actively seek out dialogue, both with the handful of fierce opponents and with the vast majority who want to benefit from the opportunities biotech brings, such as a lecture hall full of Wageningen students. Our views are fully supported by the government: in the European legislative negotiations, the Netherlands is fully committed to the progress that modern fermentation can bring.

Intellectual property's crucial role in driving innovation

While the debate around the application of new genomic plant techniques is slowly moving in the right direction, a considerable threat is lurking. Although an entirely different directive, opponents of patent law want to trade their support for the modernization of GMO legislation for a ban on patents on plant traits made with new genomic techniques. Hollandbio is happy to cooperate in securing accessibility to plant starting material for continuous innovation, but is adamantly opposed to this way of mixing the two directives that define the biotech sector. The protection of intellectual property - be it plant variety rights, patent rights or some other form - is crucial to innovation in plant breeding because it allows innovators at various points in the development process to protect their inventions, safely share knowledge, and recoup the investments they made. We have illustrated the importance of intellectual property for plant breeding in an [infographic](#).

A network to be proud of

More and more innovative frontrunners recognize themselves in hollandbio and are joining our ranks. We certainly provide sufficient networking opportunities to strengthen this young sector. In addition to biotech-wide events, we organized an inspiring meeting at De Kas for biotech companies active in food and materials, hosted several smaller member meetings and get-togethers, and attended various third-party events. In the coming years, we will continue to invest in the growth of our network and have planned many networking activities. After all, the stronger the network, the stronger we can represent our sector. But that's not all: our network also facilitates cooperation and increases the visibility of biotech innovations across society.



The work ahead

With the program technology for a brighter future we pave the way for the smart solutions that biotech brings for progress without downside. That is why we are working on:

The Netherlands leading the way in fermented food

The Dutch government has big ambitions when it comes to the protein transition and sustainability. Innovative food fermentation should not be left out as a crucial part of the solution to realize our goals. Fortunately, the Dutch House of Representatives agrees, and has passed several motions to this effect. The House asked the government to ascertain how it supports innovative food fermentation and to identify policy that would allow Dutch fermentation companies to maintain their leading position. The House also called on the government to identify and remove bottlenecks in the European Novel Foods procedure, which the innovative frontrunners in hollandbio's constituency see as one of the major obstacles to success. Of course, hollandbio is advising and assisting the House as well as the government in achieving the desired results.

Take that foot off the brakes

The biotech sector faces headwinds. When it comes to biotech, the national and European governments sometimes step on the gas and the brakes at the same time, resulting in a standstill. For example, the economic and social ambitions of one ministry are thwarted by the disproportionate safety requirements and risk aversion of another; or in a well-intentioned attempt at legal clarification of inappropriate and outdated legislation, a ministry loses sight of the potentially disastrous impact of such legal clarification on the goals of another ministry, or on the sector itself. Hollandbio is committed to breaking these deadlocks by identifying problems, bringing together the various perspectives and interests, and pushing for a responsible solution. Examples include the classification of microbial cultures, the presence of recombinant DNA in cultured products, and the excessively complex and strict regulation of genetic modification for both environmental introduction and controlled use. And we want to

permanently prevent the emergence of these tricky problems by insisting on a comprehensive governmental approach when it comes to biotech.

A circular economy within reach

Although the circular economy is a hot topic with governments, hollandbio believes the focus is still too much on making the established and polluting chains sustainable, while the emergence and disruptive potential of biotech is overlooked. It's high time to change this. We see the need for government intervention and call for targeted, biotech-focused policy incentives that give innovative frontrunners a fair chance to be part of the solution.

Support for biotech

What's the one biotech story we can tell to prove to as many people as possible that biotech is one of the key solutions for a cleaner and more animal-friendly and people-friendly world? As we continually build our story, we leave no opportunity unturned to highlight the importance of biotech for a better world.

Want to know more, think along or participate?

Click on or scan the QR code or contact hollandbio's [Rianne](#) or [Leonie](#).



SMALL STEPS MAKE A BIG DIFFERENCE IN GMO REGULATION

Complex, heavily outdated and ill-suited European and national legislation for genetically modified organisms (GMOs) makes the use of modern techniques difficult for biotech researchers and entrepreneurs. As a result, we in Europe are missing the boat when it comes to exploiting and profiting from the social and economic impact that these types of biotech products can deliver.

To get policymakers on the right track, we have formulated an ambitious standpoint, studied the legislation, and examined the problems and opportunities for improvement for each biotech application. Now, together with our members and external coalitions, we are tackling the hurdles posed by each legislation, steering for maximum impact on health and sustainability.



**“In a political
minefield, we have
the moral high
ground.”**

Wieteke Wouters, hollandbio

A CRYSTAL CLEAR POSITION

Hollandbio advocates a paradigm shift, from legislation that discriminates genetic modification, to legislation that promotes development and use of safe, healthy and sustainable products regardless of the technique used to make them.

COMMITMENT ON THREE LEVELS

1

Significant acceleration of national licensing for clinical research with medical GMOs.



From **>365** to **56 days**.

2

Support of the modernization of European GMO legislation for the application of modern plant breeding techniques.



Positive attitude of the government with regard to the European Commission's proposal.

3

Shared image of the problems and solutions for contained use of genetic modification.



After a **research** among experts and users conducted in collaboration with the government.

Want to know more about GMOs?

Click on or scan the QR code.



PERSONALIZED HEALTH



When you're sick, you just want one thing: to get better. In fact, you would rather just stay healthy. But the best treatment for you is not necessarily the best treatment for someone else. After all, we are all unique. Fortunately, biotech makes personalization possible - whether you need a drug, therapy, antiviral, antibiotic, vaccine or other intervention. With smart disease models and diagnostics, we can ensure that the right treatment reaches the right person at the right time. Preferably preventively to avoid disease, but if that's not possible, then certainly as early as possible in the disease process.

Unfortunately, our healthcare system is not yet ready for personalization. After an already long, costly and risky development path, new drugs and diagnostics struggle to find their way to patients. Unsuitable assessment frameworks and financial considerations inhibit the availability and deployment of these health-bringing innovations. And under the guise of "appropriate care", more, higher and sometimes even unfeasible requirements are imposed on implementation and reimbursement. There seems to be little willingness to break that status quo. And this at a time when healthcare faces major and urgent challenges: rising demand, costs, and the shortage of healthcare professionals.

Biotech maakt het leven beter

Gezondheid op maat



Wanneer je ziek bent, wil je maar één ding: beter worden. Liever nog, blijf je gewoon gezond. Wat werkt voor jou hoort niet voor een ander te werken. Wie lijken namelijk veel op elkaar, maar tegelijkertijd zijn we ook atomaal uniek. Gelukkig kunnen we steeds beter inspelen op die unieke eigenschappen door met biotech innovaties ziekte vast te stellen, te genezen én te voorkomen.


Onze ambitie

Bereiden de juiste én beste behandeling op het juiste moment. Wanneer die behandeling er nog niet is, zetten wij ons in om deze te ontwikkelen. Wanneer er al wel een behandeling is, doen we er alles aan om ervoor te zorgen dat deze de juiste patiënten bereikt.



Waarom?

- Mensen gezond houden en ongeroepen ziekten genezen: het kan steeds beter – en meer op maat, dankzij innovatie.
- Innoveren duurt lang, is kostbaar, risicovol en toegang loopt assak. Dit zet het businessmodel onder druk.
- Zorgvraag, zorgkosten en tekort aan zorg: professionals nemen toe.
- Het bedrijfsleven ontbreekt vaak aan tafels waar oplossingen worden bedacht.



Beter behandelen met een goed gevulde dokterstas

Om de patiënt en praktijk zo goed mogelijk te bedienen, zorgen we dat innovaties zo efficiënt en optimaal mogelijk hun weg vinden van lab naar praktijk, of het nu gaat om geneesmiddelen, therapieën, diagnostiek, of vaccines. Dat vraagt om een integrale en levend zorgsysteem waarbij alle stappen in het ontwikkel- en implementatieproces naadloos op elkaar aansluiten en we kunnen leren van resultaten uit de praktijk. Per situatie beslissen de arts en patiënt samen welke behandeling het beste past.



Wij werken mee aan:

- Opslossingen waarbij gezondheidsverdiens, innovatie en betaalbaarheid hand in hand gaan
- Gezamenlijke rollen en ijfere over de toegankelijkheid van nieuwe behandelingen
- Een nationale gezondheidsdata-infrastructuur als landelijke nutsvoorziening
- Helidere en betaalbare routes om innovatieve producten naar de patiënt of de markt te brengen

© hollandbio, versie augustus 2024. Meer weten? Contact hollandbio via info@hollandbio.nl of +31 070 633 13 33.



hollandbio

Click or scan the QR code to view the infographic.



Hollandbio advocates for a radical investment in progress to innovate our way out of the healthcare stalemate. We break down the silos between prevention and treatment, between declaration and reimbursement, and between research and practice, and build a learning health system that relies on good data. A system where the various steps of innovation development, assessment, reimbursement and deployment fit seamlessly together, where innovations are given the chance to prove themselves in practice down to the level of the individual. In short: we aim for a system that enables personalized health!

A look at our results

The next step: personalized health


Today, we can proudly say that our vision to accelerate and improve the route from lab to patient - so that health gains, accessibility and innovation go hand in hand - is increasingly commonplace. After years of harsh rhetoric against our sector, where everyone was beating each other up with their own facts and figures, hollandbio managed to name and shame the polarizing and counterproductive drug policy. More and more players concluded that innovation takes a long time, is costly and risky, and requires cooperation across the healthcare ecosystem. This common awareness means now is the time to take the next big step: the transition to personalized health, where we translate the innovations of our biotech leaders into health gains - everything from prevention, data, AI and disease modeling to diagnostics and treatment.

United by data

The numbers don't lie. At hollandbio, we've been shouting this from the rooftops for years. We excel at getting to the bottom of complex issues, and are eager to share and use that knowledge to improve our common ecosystem. Take, for example, clarity around the routes that innovations must take to get to the market, or our insights into the reimbursement landscape of intramural drugs, vaccines or orphan drugs. After thorough analysis of the vaccination system, we concluded that it takes an average of no less than nine years for an EMA-registered vaccine to reach a Dutch arm - a shocking observation that has since motivated many to speed things up. Setting a good example can go a long way, too: as it turns out, after our analysis of lead times, the Ministry of Health launched its own dashboard for the lead times of "locked" and extramural medicines.

Challenge the Status Quo 2.0

Change is hard – even for champions of progress like hollandbio. And definitely when it comes to transforming our healthcare system: the stakes are high, trust is low, and rules are strict and numerous. Rather than joining forces, people tend to double down on their own. But one thing is certain: if we don't start really working together, new innovations in our rusty and creaky healthcare system will struggle more and more to find their way to the clinic, and patients will pay the bill with their health. During hollandbio's Challenge the Status Quo event, collaborating under high tensions took centerstage. We challenged participants to think outside the box, offering workshops on how to get into a yes-mindset for collaboration, how to use tensions to the benefit of collaboration, and how childlike thinking can open the gates to new solutions. It was a day full of inspiration, optimism and connection: indispensable ingredients for successful transitions. And it left us wanting more!



The work ahead

When you're sick, you just want one thing: to get better. In fact, you would rather just stay healthy. That's why hollandbio, preferably in collaboration with the entire healthcare ecosystem, works towards solutions where health gains, innovation and affordability go hand in hand:

Rules for success

We are working on trust. No one denies that personalized health is the way forward. But it's easier said than done. What's behind the distrust? What are the concerns, judgments, reservations and uncertainties of the various stakeholders? And what ground rules can we come up with - together - to address them?

A learning health system

Data as a flywheel for our health: that's how we see the future. By supporting the creation of a national health data infrastructure, we are closing the data gaps between standard care, research and innovation. This enables a learning health system, one that continuously monitors where innovations live up to, exceed or fall short of their promise. In so doing, we can deploy treatments appropriately without having to overcome towering entry barriers beforehand, and make the route from lab to clinic a lot faster and more suitable.

A well-stocked doctor's bag

We firmly believe that you can't provide personalized treatment with an empty doctor's bag. The reality of the current system, though, is that the more personalized the approach, the more arduous the journey to the clinic. For orphan drugs and gene therapies, the moment of truth is now. Even with the harbor in sight, they risk running aground. Hollandbio won't rest until the routes from lab to clinic are clear, suitable and accessible for all innovations. Certainly, and perhaps especially for the frontrunners in the transition to personalized health.

Preparing for prevention

We are fully committed to prevention. This is sorely needed, because prevention's benefits are often invisible: the better a preventive measure works, the less it seems necessary. The awful health crisis never appeared, so in hindsight the treatment can seem unwarranted. This paradox means that there is very little support for investment in the development and deployment of things like vaccines, antivirals and antibiotics. Penny wise, pound foolish. That's why hollandbio calls for disease prevention to be valued on its merits, and for the necessary rewards, manpower and resources to be allocated in kind.

Want to know more, think along or participate?

Click on or scan the QR code or contact hollandbio's [Britt](#), [Thomas](#), or [Dina](#).



TRANSPARENCY AROUND LEAD TIMES

Getting drugs faster and better from lab to patient: that's hollandbio's goal. But how long do patients have to wait after requesting a new treatment? Until recently, no one really knew; transparent, objective and up-to-date figures on lead times were lacking.


Because shared facts and figures are an indispensable first step toward effective solutions for rapid access, we set to work ourselves. Using a structured approach, we first mapped out the complex system of drug reimbursement and then made lead times transparent to all. And setting a good example worked! In late 2023, and with our help, the Ministry of Health, Wellness and Sport launched the official [government dashboard](#).

**Working together
to find the core
based on facts:
that is the strength
of hollandbio."**

Thomas Broekhoff, hollandbio




STRUCTURAL APPROACH



MEDIANE LEAD TIMES FROM EMA TO ADD-ON

(up to and including year)



THE RESULT: JOINT EFFORT FOR CHANGE



Hollandbio is an expert in this topic



Discussions based on shared facts and figures



Growing support around the problem



Government publishes data in collaboration with the sector

Want to know more about lead times?

Click on or scan the QR code.



**Raise
the bar**



hollandbio




#advocacy

THE FACE OF DUTCH BIOTECH

Hollandbio is the representative of Dutch biotech. Our commitment: to remove the obstacles that stand in the way of our frontrunners' success. To achieve this, our advocacy and sophisticated lobbying go hand in hand with communication and stakeholder management. Hollandbio puts the biotech sector on the map, communicates the results we achieve, and explains developments and current affairs. This makes us the trusted partner and leading authority in biotech, and maximizes our impact.

Prior to the House of Representatives election



In the biotech political party [online wizard](#), we showed how our commitment translates into policy.



Hollandbio's commitment in biotech's [election manifesto](#).



After the election we organized an event to [explain](#) the election results.

And, of course, after the cabinet was formed, we highlighted the [main points](#) from the coalition agreement.

Communications

The Dutch biotech sector is growing like a weed, and hollandbio is growing with it. And this is paying off, letting us devote even more time, attention and passion to putting the sector firmly on the map and promoting hollandbio.

The BITE is our well-read and highly appreciated weekly newsletter – both within and beyond our membership – where we share national and international developments in the sector and news about members, explain current affairs in politics and policy, communicate hollandbio’s results, and occasionally voice our opinions out loud.



We are growing continuously on LinkedIn with more than

12,000 followers.



Our BITE newsletter reaches a weekly

3,000 subscribers.



The hollandbio website attracts many visitors constantly, on average

6.000 per month.



On X (formerly Twitter) we have more than

2,300 followers.

We also make use of other communication channels, such as our website and LinkedIn. We’re reaching more and more people with our messages, partly thanks to our growing number of followers. But the impact of traditional media should not be underestimated, which is why we maintain relationships with journalists, who regularly and gratefully make use of our expertise and opinions.

fd. Mijn nieuws Net binnen Beurs ▾ Krant Podcasts FD Persoonlijk Boeken

Opinie • 16 juli 09:00

Door oplopende inflatie is uw gezondheid een stuk minder waard in de ogen van de overheid

Annemiek Verkamman

De cijfers waarop overheid en zorgverzekeraars zich baseren om tot een kosteneffectieve zorg te komen, stijgen niet mee met de inflatie. En dat leidt tot een rem op het aantal gezonde levensjaren, schrijft Annemiek Verkamman.

In 'The Financial Daily Newspaper', focused on business.

eiwit trends Grondstoffen Innovatie Business Retail Onze experts

Weet wat er speelt in de eiwittransitie

← Terug naar interviews

Biotech cruciaal in de eiwittransitie

Biotech is cruciaal in de eiwittransitie, zegt Annemiek Verkamman van hollandbio. Om onze leidende positie in de voedselvoorziening te behouden, is het belangrijk dat de rode loper wordt uitgerold voor innovatie.

25-06 Updated on: 23-07 Interview Innovatie



Annemiek Verkamman, managing director van hollandbio. Foto: hollandbio

In 'Eiwittrends', focused on protein innovation.



"Ze zeiden dat het bloed, zweet en tranen zou kosten en dat was ook zo."

Judith Vivité
Single Cell Discoveries

hollandbio

We spotlight entrepreneurs.

Stakeholder management

The success of our lobby relies on decision makers and key organizations knowing who we are and what we do. That's why we're strengthening hollandbio as a trusted partner and a leading authority in our field. This requires a smart approach because there is ample choice, and maintaining all of these relationships is no easy task. We invest heavily in relationships with ministries, members of parliament and important partners. Our strong network helps us realize hollandbio's goal: that we're always involved early and at the right level in new or changing legislation, regulations and policies that affect the success of our exquisite biotech sector.



Visiting [BaseClear](#) in Leiden with VVD house member [Pim van Strien](#).

Visiting [KeyGene](#) in Wageningen with political parties NSC and BBB.




Together with the Ministry of Economic Affairs and the Netherlands Enterprise Agency (RVO) at [Genmab](#) at the Utrecht Science Park.



With PvdD's lead delegate Anja Hazekamp (MEP) at [The Protein Brewery](#) in Breda.

With the Minister for Foreign Trade, Reinette Klever, during [BIO-Europe](#) in Stockholm, Sweden.





Razor-sharp opinions and analyses

Ja, we kunnen onze medicijnen vertrouwen

GEZONDHEID OP MAAT, GEZONDHEID

19 JUNI 2024

In een aanzijlige langraad vol stemmingsmakerij, olokbait titel inclusie, trekt dagblad **Trouw** opzichte een groot goed in twijfel: ons vertrouwen in nieuw geregistreerde geneesmiddelen. Dat doet de krant bovendien over de rug van het Europese Medische Agentschap (EMA): de in Amsterdam gevestigde, toonaangevende autoriteit die streng toeziet op de veilige toelating van nieuwe geneesmiddelen in de EU. Het medium wakkerd zo het toch al wankel vertrouwen in overheidsinstituten aan. Een gevaarlijke ontwikkeling, vindt hollandbio, waarmee zij in dit geval letterlijk levens op het spel zet.

EMA neemt steeds vaker genegen met mager wetenschappelijk bewijs om geneesmiddelen toe te laten tot de Europese markt, zo neemt Trouw klakkeloos over van Investigatie Europe (IE), een internationaal collectief geband op het ontmantelen van de 'verborgen structuren die Europa vandaag de dag vormgeven'. De oorzaak van EMA's

Hollandbio solliciteert bij VWS

GEZONDHEID OP MAAT, GEZONDHEID, UITSLICHT

12 NOVEMBER 2024

Het ministerie van VWS wil de ontwikkeling van nieuwe geneesmiddelen stimuleren en heeft daarvoor zelfs een vacature openstaan. Zo'n rol is hollandbio natuurlijk op het lijf geschreven. Al verriegen we graag enkele accenten in de functiemaatschappij, zodat de nieuwe beleidsmidwarker daadwerkelijk bij kan dragen aan een ecosysteem waarin gezondheidswinst, innovatie en betaalbaarheid echt hand in hand gaan.

Geachte mevrouw Agema, beste Fleur,

Elke dag zetten wij ons in om te werken aan een maatschappij waarin biotech maximaal bijdraagt aan gezondheid, duurzaamheid en economische groei. Geen wonder dat wij ons direct aangesproken voelden door de vacature van [Senior beleidsmidwarker innovatie geneesmiddelen](#) bij het ministerie van VWS. Met deze brief lichten we graag toe waarom

Liever lege supermarktschappen dan oetdrooien

TECHNOLOGIE VOOR EEN DUURZAME TOEKOMST, DUURZAAMHEID & VOEDING, UITSLICHT

20 MAART 2024

Tijdens het recente Tweeminuten debat Biotechnologie nam de Tweede Kamer een drietal moties aan die - al dan niet bewust - flink roet in het eten gooien voor het spoedig benutten van nieuwe technieken voor plantenveredeling (NGT) in Europa. Met het samenmen van deze moties vraagt de Kamer het kabinet als het gaat om onze voedselproductie net zo hard op het gaspedaal als op de rem te gaan staan. Liever lege supermarktschappen dan oetdrooien, zo lijkt de gedachte.

De vele toonaangevende plantenveredelaars die Nederland rijk is, staan te trappelen om eindelijk moderne technieken te kunnen benutten om sneller en efficiënter nieuwe gewassen te ontwikkelen die bijdragen aan de wereldwijde voedselvoorziening en verduurzaming van de landbouw. Door buitenproportioneel zware en gedateerde Europese

Dutch Life Sciences Trend Analysis 2024: Market is slowly picking up

PUBLICATIE, FINANCIERING, SECTORING

2 APRIL 2024

Biotechgate, the leading global biotech database, published their annual Trend Analysis Report 2024 of the Dutch life sciences sector. In 2022, the Dutch biotech landscape saw a sharp 50% decline in venture financing, reflecting the challenging global economic climate. Fortunately, the tide seems to turn. In 2023, life sciences saw a remarkable 50% rise in funding, underscoring the sector's resilience and growth potential. Headlines included Victor!, Kymriis, Mautbio, and Varmid. This year's Trend Analysis benchmarks Dutch and other European biotech with the US. As one of the striking differences, US biotech has three times as many assets in clinical development per capita compared to their Dutch counterparts, illustrating the stark contrast in financial ecosystems, the availability of funding in the US still far outranks funds in Europe.

Want to know more, think along or participate?

Contact hollandbio's [hollandbio's Timen](#), [Casper](#), [Dina](#) of [Idalia](#).



#events

HOLLANDBIO'S EVENTS CONNECT THE SECTOR

At the many [events](#) organized by hollandbio, there is ample opportunity for networking and knowledge exchange. Our network helps bring the sector together. From top-notch speakers to the excellent expertise, from original locations to the distinctive character of the events, and of course the drinks - we are proud of the high praise we receive time and again. Meet the network of hollandbio!



Curious about hollandbio's events?

Click or scan the QR code for our offer.





Hollandbio's Year Event 2024

Click or scan the QR code to read the report.



Dutch Biotech Event


Click or scan the QR code to read the report.





Challenge the Status Quo

Click or scan the QR code to read the report.





Biotech for a sustainable future

Click or scan the QR code to read the report.





Hollandbio komt naar je toer

Click or scan the QR code to read the reports.



#advantages

MEMBER BENEFITS

Running a biotech company is demanding and challenging. Not to mention the courage, dedication and perseverance it requires. With our member benefits, hollandbio makes doing business in biotech a bit easier for our members. Discover the possibilities for you!



Discounts to events

Discounts to leading national and international events.

Partnering conferences and events are essential in biotech. Whether you're looking for knowledge, investors, customers, partners or technology, professional conferences are the place to be. Hollandbio negotiates member discounts on registration fees for the best biotech events. You'll find the current deals on our website.

In 2024, hollandbio members had the opportunity to visit over 50 events at home and abroad at a discount.



Hollandbio partners

Meet the hollandbio partners.

At hollandbio, we know better than anyone that doing business in biotech is expensive. Our partner program brings together a slew of valuable offerings. Take advantage of special deals and discounts, from access to innovative services to markdowns on lab materials. Discover the current offerings from hollandbio partners on the website and get more out of your membership.

In 2024, the purchasing program with Fisher Scientific saved hollandbio members over a million euros. Thanks to this discount, 40 of the 70 participating companies even recouped their membership fees!



Want to know more, think along or participate?

Click on or scan the QR code or contact hollandbio's [Max](#).



#join us

JOIN HOLLANDBIO

Become a member today and...

- Gain access to our network
- Put your organization in the spotlight
- Have a say in our advocacy efforts
- Stay informed of relevant biotech developments in the Netherlands and beyond
- Participate in our programs
- Meet peers, experts and stakeholders at our events
- Profit from our member benefits and deep discounts

Hollandbio is ready for you!



Sign up?

Click or scan the QR code for more information.


A bigger taste for biotech?



Stay up to date:

Click or scan the QR code to sign up for our weekly BITE newsletter.





Colophon

Concept, editorial and production: Hollandbio

Images: Hollandbio, Nils van Houts

Design: Jacob & Jacobus

© hollandbio January 2025

Visiting address

Laan van Nieuw Oost Indië 131-133
2593 BM The Hague

Mailing address

Laan van Nieuw Oost Indië 133 M
2593 BM The Hague
+31 (0) 70 833 1333
info@hollandbio.nl



Leadpharma



LEVELS
diagnostics



LI-COR



lygature
pioneering medicine
together.



MAT
RESEARCH

Match2Win
krachtig in verbonden



MEATABLE



MERCK

Mercurna

Merus

mibiton

MIMETAS
the organ-on-a-chip company

moderna

MOSA
Meat



MYLIFE TECHNOLOGIES



NautaDutilh



neogene



NOVARTIS



NTrans
Technologies



octoRelease

OFICHEM
GROUP



Oncode
Institute



Orchard
therapeutics

Orfenix



PathoFinder®



Pharming

PHARVARIS

PHC
GROUP



pivotpark
screeningcentre

pivotpark
Europe's foremost biopharmaceutical campus

planet b.io



PLUVIA

polpharma
biologics

PROGRESS

propharma



ProteoNic

Public Eyes



QORIUM

Qurin

QVQ
SOLUTIONS IN ANTIBIOTICS

Rapidemic

RIBOPRO



sabiad
INDUSTRIAL BIOTECHNOLOGY CENTER

Sairopα

Salvius

sanofi

SentryX

SARSTEDT

Scalable
LIFE · SCIENCES

Scenic
Biotech



SCINUS
CELL EXPANSION

scope
biotechnologies

Scribes | tax lawyers

Seagen

SentryX

shanx
medtech

simmons
simmons

SINGLE CELL
DISCOVERIES

SkylineDX

slg
shadow lake group

SBTIC
Slovak Biotechnology Cluster

Solynta
true potato seeds

specs



STAR DUB
Experts in Regulatory Affairs

Subli

SURFIX
diagnostics



Synaffix
connect to cure

SYNERKINE
PHARMA
CREATING INNOVATIVE PAIN SOLUTIONS

SYNGLE
THERAPEUTICS

TARGED
TARGETED ENZYME DELIVERY

tebio

TEMPLE
THERAPEUTICS



THOSE VEGAN
COWBOYS

TNO

toxys

TREWAY

TTOPSTART

Tuyacoz
Healthcare Solutions
Perfection People Planet

TwinPharma

UbiQ
targeting the ubiquitin system

uniQure



UTRECHT
SCIENCE
PARK



VectorY
THERAPEUTICS

Venn Life Sciences

VERTEX
THE SCIENCE OF POSSIBILITY

VICO
Therapeutics

VINTURA

VitalNext
Food for special
medical purposes

VitroScan

vivici

VTU

westburg
LIFE SCIENCES

ZOBIO

ZWIERS
Regulatory Consultancy
A ProductLifeGroup Company



[linkedin.com/company/hollandbio/](https://www.linkedin.com/company/hollandbio/)
x.com/hollandbio
hollandbio.nl
info@hollandbio.nl

hollandbio